Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Polynovo (PNV) has received US$15 million (nearly A$22 million) from the Biomedical Advanced Research and Development Authority (BARDA)
  • The funding is to support its synthetic dressing, NovoSorb BTM, receiving U.S. Food and Drug Administrations (FDA) approval
  • Last week, the FDA told the company it needs more information on the product
  • Additionally, Polynovo will also make a modest co-funding contribution, which will be announced after it receives FDA approval
  • Polynovo is down 1.71 per cent and is trading for $2.30 each

Polynovo (PNV) has received US$15 million (nearly A$22 million) from the U.S. Department of Health to support the NovoSorb BTM pivotal trial program.

Last week, the company received feedback from the U.S. Food and Drug Administration (FDA) on its pivotal trial protocol. The FDA asked for more information and a formalisation of the trial's review points. Due to this, trial recruitment could be delayed.

NovoSorb BTM is a synthetic dressing that is used to treat severe burns and wounds, where there is a significant loss of flesh.

The pivotal trial will support future submissions leading to pre-market approvals.

The funding came from the Biomedical Advanced Research and Development Authority (BARDA). Additionally, Polynovo will make a modest co-funding contribution to the trail, with the final budget to be announced after it received U.S. FDA approval.

The trial will gather extensive data on the effectiveness of Novosorb in treating burns. The product has already been approved outside of the U.S.

“We appreciate BARDA’s ongoing commitment to NovoSorb BTM in funding this trial," Paul said.

"Their substantial non-dilutive funding for this and other programs better enables PolyNovo to bring our innovative, life-saving products to the U.S. and the rest of the world," he added.

Polynovo is down 1.71 per cent and is trading for $2.30 each at 12:36 pm AEST.

PNV by the numbers
More From The Market Herald
John Poynton denies making Crown bid

" John Poynton denies making Crown bid

One of Perth’s most prominent corporate advisors John Poynton was the first witness called yesterday when evidence resumed at the Perth Casino Royal Commission.
Regis Resources (ASX:RRL) - Managing Director and CEO, Jim Beyer - The Market Herald

" Regis Resources (ASX:RRL) increases production in Q2 after Tropicana buy

Regis Resources (RRL) increased production in the June quarter following the 30 per cent acquisition of the Tropicana Gold Project in Western Australia.
PointsBet (ASX:PBH) - CEO, Sam Swanell - The Market Herald

" PointsBet (ASX:PBH) plans $400m cap raise, releases June quarterly

Bookmaker PointsBet (PBH) is set to undertake a $400 million capital raising to strengthen its balance sheet.
Fortescue Metals (ASX:FMG) - CEO, Elizabeth Gaines - The Market Herald

" Fortescue Metals (ASX:FMG) sets new export records as iron ore prices rally

Fortescue Metals (FMG) has been making the most of the recent iron ore prices, setting new export records for both the quarter and